급성 편두통 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 치료별, 투여 경로별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Acute Migraine Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment, By Route of Administration, By Distribution Channel, By Region & Competition, 2020-2030F
세계의 급성 편두통 치료제 시장 규모는 2024년에 23억 5,000만 달러에 달하며, 2030년까지 연간 평균 성장률(CAGR)은 4.80%로 예측 기간 중 안정된 성장이 전망되고 있습니다.
이 시장은 편두통(심한 두통을 특징으로 하며 종종 메스꺼움, 구토, 광과민증을 동반하는 쇠약해진 신경질환)으로 고통받는 사람들의 긴급한 의료 수요에 대응하는 데 초점을 맞추고 있는 제약 산업에서 중요한 부문입니다. 편두통의 증상을 완화하고 재발을 억제하기 위해 고안된 다양한 의약품 솔루션이 포함됩니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
23억 5,000만 달러 |
| 시장 규모 : 2030년 |
31억 2,000만 달러 |
| CAGR: 2025-2030년 |
4.80% |
| 급성장 부문 |
예방 |
| 최대 시장 |
북미 |
주요 시장 성장 촉진요인
주요 시장이 해결해야 할 과제
주요 시장 동향 :
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 급성 편두통 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 치료별(예방, 진통)
- 투여 경로별(경구, 주사, 점비약, 기타)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024)
- 시장 맵
제6장 북미의 급성 편두통 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 북미 : 국가별 분석
제7장 유럽의 급성 편두통 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 급성 편두통 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 아시아태평양 : 국가별 분석
제9장 남미의 급성 편두통 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 급성 편두통 치료제 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 급성 편두통 치료제 시장 : SWOT 분석
제14장 경쟁 구도
- Endo International PLC
- AbbVie Inc.
- Impax Laboratories LLC
- Glaxo Smith Kline PLC
- Astellas Pharma Inc
- Amgen Inc
- Bayer AG
- AstraZeneca PLC
- Dr. Reddy's Laboratories Ltd
- Eli Lilly and Company
- Pfizer Inc
제15장 전략적 제안
제16장 조사회사 소개·면책사항
KSA
The global Acute Migraine Drugs Market was valued at USD 2.35 billion in 2024 and is projected to experience consistent growth during the forecast period, with a compound annual growth rate (CAGR) of 4.80% through 2030. This market represents a critical segment within the pharmaceutical industry, focusing on addressing the immediate medical needs of individuals suffering from migraines-a debilitating neurological disorder characterized by severe headaches, often accompanied by nausea, vomiting, and light sensitivity. It includes a range of pharmaceutical solutions designed to alleviate symptoms during migraine episodes and reduce their recurrence.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 2.35 Billion |
| Market Size 2030 | USD 3.12 Billion |
| CAGR 2025-2030 | 4.80% |
| Fastest Growing Segment | Preventive |
| Largest Market | North America |
Key Market Drivers:
1. Increasing Global Prevalence of Migraine: The rising global prevalence of migraine is a major driver of growth in the Global Acute Migraine Drugs Market. Between 1990 and 2021, the global migraine burden increased significantly, with prevalence rising by 58.15%, from 732.56 million to 1.16 billion cases. The incidence rate also climbed by 42.06%, signaling a notable surge in newly diagnosed cases. Furthermore, Disability-Adjusted Life Years (DALYs) linked to migraines increased by 58.27%, highlighting the growing health and economic burden of the condition worldwide. This surge points to an expanding market opportunity for acute migraine treatments as pharmaceutical companies and healthcare providers address the increasing demand for effective solutions. As the number of migraine sufferers grows, the demand for fast-acting and specialized treatments rises correspondingly. Migraines are among the most common neurological disorders, affecting millions globally, and are recognized as one of the leading causes of disability, according to health organizations such as the World Health Organization (WHO) and the Global Burden of Disease Study. The rising number of patients seeking treatment is directly contributing to the expanding market for acute migraine drugs, with both prescription and over-the-counter (OTC) medications seeing increased sales and revenue potential. The growing prevalence is not limited to specific demographics, as it spans across various age groups and regions, offering new opportunities for pharmaceutical companies.
Key Market Challenges:
1. Regulatory Barriers and Stringent Approval Processes: Regulatory approvals are essential for ensuring patient safety but can also present challenges in the development and commercialization of new migraine drugs. Regulatory agencies like the FDA and EMA impose strict criteria, requiring extensive clinical trials, meticulous data collection, and significant time and resource investment. The extended approval timelines can delay the market introduction of innovative migraine treatments, limiting patient access to potentially improved options and impacting pharmaceutical companies' revenue streams. To address this, companies must adopt proactive engagement strategies with regulatory bodies, such as early communication, well-designed clinical trials, and thorough data collection efforts to expedite the approval process.
Key Market Trends:
1. Personalized Medicine and Targeted Therapies: Personalized medicine is transforming the migraine treatment landscape by tailoring therapies to individual patient profiles, taking into account genetic, lifestyle, and clinical factors. Targeted therapies address the underlying mechanisms of migraine attacks, improving treatment efficacy and minimizing adverse effects, thereby enhancing patient outcomes. This trend meets growing patient demand for more effective solutions and drives innovation and market expansion. Pharmaceutical companies are investing in research to identify biomarkers and genetic factors linked to migraine susceptibility, leading to the development of drugs with precise mechanisms of action that offer personalized treatment options for patients.
Key Market Players:
- Endo International PLC
- AbbVie Inc.
- Impax Laboratories LLC
- GlaxoSmithKline PLC
- Astellas Pharma Inc.
- Amgen Inc.
- Bayer AG
- AstraZeneca PLC
- Dr. Reddy's Laboratories Ltd
- Eli Lilly and Company
- Pfizer Inc.
Report Scope: The Global Acute Migraine Drugs Market has been segmented as follows, along with detailed industry trends:
By Treatment:
- Preventive
- Pain Relieving
By Route of Administration:
- Oral
- Injectable
- Nasal Sprays
- Other
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America (United States, Canada, Mexico)
- Europe (France, United Kingdom, Italy, Germany, Spain)
- Asia-Pacific (China, India, Japan, Australia, South Korea)
- South America (Brazil, Argentina, Colombia)
- Middle East & Africa (South Africa, Saudi Arabia, UAE)
Competitive Landscape: In-depth analysis of major companies within the Global Acute Migraine Drugs Market.
Customization Options Available: TechSci Research offers tailored solutions for the Global Acute Migraine Drugs market report based on specific company needs.
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Acute Migraine Drugs Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Treatment (Preventive, Pain Relieving)
- 5.2.2. By Route of Administration (Oral, Injectable, Nasal Sprays, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.4. By Region
- 5.2.5. By Company (2024)
- 5.3. Market Map
6. North America Acute Migraine Drugs Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Treatment
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Acute Migraine Drugs Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Treatment
- 6.3.1.2.2. By Route of Administration
- 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Acute Migraine Drugs Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Treatment
- 6.3.2.2.2. By Route of Administration
- 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Acute Migraine Drugs Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Treatment
- 6.3.3.2.2. By Route of Administration
- 6.3.3.2.3. By Distribution Channel
7. Europe Acute Migraine Drugs Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Treatment
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Acute Migraine Drugs Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Treatment
- 7.3.1.2.2. By Route of Administration
- 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Acute Migraine Drugs Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Treatment
- 7.3.2.2.2. By Route of Administration
- 7.3.2.2.3. By Distribution Channel
- 7.3.3. Italy Acute Migraine Drugs Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecasty
- 7.3.3.2.1. By Treatment
- 7.3.3.2.2. By Route of Administration
- 7.3.3.2.3. By Distribution Channel
- 7.3.4. France Acute Migraine Drugs Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Treatment
- 7.3.4.2.2. By Route of Administration
- 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Acute Migraine Drugs Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Treatment
- 7.3.5.2.2. By Route of Administration
- 7.3.5.2.3. By Distribution Channel
8. Asia-Pacific Acute Migraine Drugs Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Treatment
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Acute Migraine Drugs Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Treatment
- 8.3.1.2.2. By Route of Administration
- 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Acute Migraine Drugs Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Treatment
- 8.3.2.2.2. By Route of Administration
- 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Acute Migraine Drugs Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Treatment
- 8.3.3.2.2. By Route of Administration
- 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Acute Migraine Drugs Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Treatment
- 8.3.4.2.2. By Route of Administration
- 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Acute Migraine Drugs Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Treatment
- 8.3.5.2.2. By Route of Administration
- 8.3.5.2.3. By Distribution Channel
9. South America Acute Migraine Drugs Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Treatment
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Acute Migraine Drugs Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Treatment
- 9.3.1.2.2. By Route of Administration
- 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Acute Migraine Drugs Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Treatment
- 9.3.2.2.2. By Route of Administration
- 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Acute Migraine Drugs Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Treatment
- 9.3.3.2.2. By Route of Administration
- 9.3.3.2.3. By Distribution Channel
10. Middle East and Africa Acute Migraine Drugs Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Treatment
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Acute Migraine Drugs Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Treatment
- 10.3.1.2.2. By Route of Administration
- 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Acute Migraine Drugs Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Treatment
- 10.3.2.2.2. By Route of Administration
- 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Acute Migraine Drugs Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Treatment
- 10.3.3.2.2. By Route of Administration
- 10.3.3.2.3. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Acute Migraine Drugs Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Endo International PLC
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. AbbVie Inc.
- 14.3. Impax Laboratories LLC
- 14.4. Glaxo Smith Kline PLC
- 14.5. Astellas Pharma Inc
- 14.6. Amgen Inc
- 14.7. Bayer AG
- 14.8. AstraZeneca PLC
- 14.9. Dr. Reddy's Laboratories Ltd
- 14.10.Eli Lilly and Company
- 14.11.Pfizer Inc
15. Strategic Recommendations
16. About Us & Disclaimer
